Zhang Financial’s Protalix BioTherapeutics PLX Stock Holding History

Zhang Financial’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,500	Closed	-$9K	–	105
2019 Q3	$9K	Hold	4,500	–	–	﹤0.01%	87
2019 Q2	$21K	Hold	4,500	–	–	0.01%	90
2019 Q1	$20K	Hold	4,500	–	–	0.01%	86
2018 Q4	$14K	Hold	4,500	–	–	0.01%	82
2018 Q3	$34K	Buy	+4,500	New	+$22.6K	0.02%	78
2018 Q2	–	Sell	-4,500	Closed	-$23K	–	79
2018 Q1	$23K	Hold	4,500	–	–	0.01%	77
2017 Q4	$33K	Hold	4,500	–	–	0.02%	82
2017 Q3	$27K	Hold	4,500	–	–	0.01%	81
2017 Q2	$36K	Hold	4,500	–	–	0.02%	77
2017 Q1	$33K	Buy	+4,500	New	+$40.5K	0.02%	79

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Zhang Financial's PLX Position: Q4 2019 in Review

Zhang Financial sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 4,500 shares — an estimated $9K sold.

Zhang Financial first reported a position in PLX in Q1 2017 and held it in 10 quarters. The position peaked at $36K in Q2 2017. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

Zhang Financial reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
Zhang Financial sold 4,500 Protalix BioTherapeutics shares in Q4 2019, an estimated $9K.
Zhang Financial first reported a position in Protalix BioTherapeutics in Q1 2017 and held it in 10 quarters.
Zhang Financial's Protalix BioTherapeutics position peaked at $36K in Q2 2017.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on Zhang Financial's 13F filing for Q4 2019, filed 21 Jan 2020.